human her2 bc cell lines mdamb361  (ATCC)

Journal: Scientific Reports

Article Title: Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer

doi: 10.1038/s41598-025-14639-z

Figure Lengend Snippet: Biological features of HER2 + BC cells and cytotoxic activity of putative virtual hits. ( A ) Percentage (%) of CD36 + cells in HER2 + BC cell lines HCC1569, MDAMB361, EFM192A and BT474 evaluated by flow cytometry analysis; ( B ) CD36 relative median fluorescence intensity (rMFI) of HER2 + BC cell lines HCC1569, MDAMB361, EFM192A and BT474 evaluated by flow cytometry analysis; ( C ) Analysis of FA uptake in HCC1569, MDAMB361, EFM192A and BT474 cells incubated with fluorescent Bodipy-C16 assay for 30 min evaluated by Bodipy FL C16 uptake assay; ( D ) Tumor proliferation of HCC1569 and ( E ) MDAMB361 cells upon exposure for 96 h to 25 µM and 50 µM of putative anti-CD36 inhibitors 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , and 15 evaluated by an SRB bioassay. Values were normalized to the growth of the cells incubated with DMSO. The data are presented as the means ± SEMs ( n = 3). Significance was calculated by using a two-tailed paired Student’s t test.

Article Snippet: Human HER2 + BC cell lines MDAMB361 , HCC1569 , , EFM192A and BT474 with different sensitivity to anti-HER2 drugs were purchased from American Type Culture Collection (ATCC; Rockville, MD, USA).

Techniques: Activity Assay, Flow Cytometry, Fluorescence, Incubation, Bioassay, Two Tailed Test

Journal: Scientific Reports

Article Title: Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer

doi: 10.1038/s41598-025-14639-z

Figure Lengend Snippet: Cytotoxic activity and apoptotic cell death of HER2 + BC cells upon exposure to 11 and 13. ( A ) Cytotoxic activity of 11 and ( B ) of 13 anti-CD36 hit compounds on HCC1569, MDAMB361 and BT474 cells incubated with SSO; tested at 50 µM and 100 µM, and 11 and 13 hits tested at 12.5 µM, 25 µM, 50 µM, for different time intervals (48 h, 72 h and 96 h), respectively; and subsequently evaluated by the cytotoxic SRB bioassay. Data are presented as the means ± SEMs ( n = 3–5). Significance was calculated using a two-tailed paired t test. ( C ) and ( D ) Apoptotic activity (Casp-3) of HCC1569 cells, and ( E ) and ( F ) of MDAMB361 cells evaluated after exposure to 11 (upper panel) and 13 (lower panel) CD36 inhibitors at 25 and 50 µM for different times (48 h, 72 h and 96 h), respectively. Data are presented as the means ± SEMs ( n = 3). Significance was calculated by using a two-tailed paired Student’s t test.

Article Snippet: Human HER2 + BC cell lines MDAMB361 , HCC1569 , , EFM192A and BT474 with different sensitivity to anti-HER2 drugs were purchased from American Type Culture Collection (ATCC; Rockville, MD, USA).

Techniques: Activity Assay, Incubation, Bioassay, Two Tailed Test

Journal: Scientific Reports

Article Title: Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer

doi: 10.1038/s41598-025-14639-z

Figure Lengend Snippet: FA uptake in HER2 + BC cell lines treated with hit compounds 11 and 13. HCC1569 (upper) and MDAMB361 (lower) cells were incubated with 11 and 13 (25 µM) for 60 min in the presence of palmitic acid conjugates with bovine serum albumin. FA uptake was assessed using gas chromatography-flame ionization detector (GC-FID) analysis. Data are presented as fold increase (FI) values (treatment versus control) calculated from the normalized C16:0 content. Results are presented as the means ± SEMs ( n = 3). Significance was determined using a two-tailed paired Student’s t test.

Article Snippet: Human HER2 + BC cell lines MDAMB361 , HCC1569 , , EFM192A and BT474 with different sensitivity to anti-HER2 drugs were purchased from American Type Culture Collection (ATCC; Rockville, MD, USA).

Techniques: Incubation, Gas Chromatography, Control, Two Tailed Test

Journal: Scientific Reports

Article Title: Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer

doi: 10.1038/s41598-025-14639-z

Figure Lengend Snippet: Tumor proliferation of HCC1569 cells after treatment with lapatinib, 11 or 13 tested as a monotherapy and in combination with the anti-HER2 agent. ( A – D ) Proliferation of HCC1569 cells after exposure to lapatinib (7.2 µM), 11 or 13 CD36 inhibitors (12.5 µM and 25 µM) alone or in combination, as evaluated by SRB assay. HCC1569 cells were incubated with 11 tested at ( A ) 12.5 µM or ( B ) 25 µM, or with 13 tested at ( C ) 12.5 µM or ( D ) 25 µM alone or in combination for 48–72 h. Results are presented as the mean ± SEM ( n = 3/4). Significance was calculated using a two-tailed paired t test.

Article Snippet: Human HER2 + BC cell lines MDAMB361 , HCC1569 , , EFM192A and BT474 with different sensitivity to anti-HER2 drugs were purchased from American Type Culture Collection (ATCC; Rockville, MD, USA).

Techniques: Sulforhodamine B Assay, Incubation, Two Tailed Test